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ABSTRACT

Introduction The incidence and mortality rates of
cutaneous melanoma (CM) are increasing among fairskinned populations worldwide. Ultraviolet radiation (UVR)
is the principal risk factor for CM, but is also the main
source of 25-hydroxyvitamin D (25(OH)D), which has been
associated with reduced risk and better prognosis of some
cancer types. However, both low and high 25(OH)D levels
have been associated with increased risk of CM. Obesity
as measured by body mass index (BMI) is associated with
risk of several cancers and has also been suggested as a
risk factor for CM, and may also be related to insufficient
25(OH)D and/or high leptin levels. Moreover, contracting a
CM diagnosis has been associated with increased risk of
developing second cancer. We aim to study whether low
prediagnostic serum levels of 25(OH)D, high prediagnostic
levels of BMI and high serum leptin levels influence CM
incidence, Breslow thickness and CM mortality, and risk of
second cancer and survival after a CM diagnosis.
Methods and analysis Cohort and nested case–control
studies will be carried out using the population-based
Janus Serum Bank Cohort (archival prediagnostic sera,
BMI, smoking and physical activity), with follow-up from
1972 to 2014. Additional data will be received from the
Cancer Registry of Norway, the national Cause of Death
Registry, Statistics Norway (education and occupation)
and exposure matrices of UVR. Time-to-event regression
models will be used to analyse the cohort data, while
the nested case–control studies will be analysed by
conditional logistic regression. A multilevel approach will
be applied when incorporating group-level data.
Ethics and dissemination The project is approved by
the Regional Committee for Medical Research Ethics
and is funded by the Norwegian Cancer Society. Results
will be published in peer-reviewed journals, at scientific
conferences and in the news media.

Introduction
Rationale and evidence gaps
Ultraviolet radiation (UVR) is a recognised
human carcinogen and the principal environmental risk factor for cutaneous melanoma
(CM),1 2 while skin characteristics such as
skin sensitivity and number of naevi indicate CM susceptibility.3–7 CM incidence and

Strengths and limitations of this study
►► Linkage of independent, national data sources by

use of a unique personal identification number for
a comprehensive research file and complete control
of loss to follow-up.
►► Prediagnostic serum samples assuring a true
prospective relationship between exposures and
cancer, limiting bias introduced by reverse causality.
►► Lifetime ambient ultraviolet radiation (UVR) exposure
data (UVA, UVB and erythemally weighted UV) and
group-level data on sunburns, sunbathing vacations
and solarium use capturing variations in age, time
period and county of residence.
►► Ambient UVR exposure and data on sunburns,
sunbathing vacations and solarium use can only be
linked to the Janus Cohort on a group level.
►► Lack of data on pigmentary characteristics and
naevi.

mortality rates have been increasing in fairskinned populations worldwide the past
decades, and CM is currently the third most
common cancer in Europe after cancers of
the colon/rectum and the lung.8 9 In Norway,
CM incidence has increased more than 3%
annually between 1982 and 2011 and has
been projected to continue to rise.9 Excess
UVR exposure is likely the major cause of this
increase,10 but also low vitamin D levels and
obesity have been suggested to play a role.11 12
Vitamin D synthesis in the skin is initiated by UVR exposure to the skin surface at
wavelengths of 290–320 nm, which converts
7-dehydrocholesterol in the keratinocytes to
previtamin D3 (cholecalciferol). Together
with previtamin D2 (ergocalciferol), previtamin D3 may also be obtained by diet. Both
previtamin D2 and D3 are then hydroxylated in the liver to 25-hydroxyvitamin D
(25(OH)D), which represents the circulating storage form of vitamin D. A second
hydroxylation in the kidney converts vitamin
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D to its biologically active form 1, 25-hydroxyvitamin D
(1, 25(OH)D),13 14 which has been associated with anticancer mechanisms.13 15–17 Based on four studies, a recent
meta-analysis reported a summary relative risk of CM of
1.46 (95% CI: 0.60 to 3.53) for the highest compared
with the lowest (reference) quantile of 25(OH)D.12 In
three of these studies, risks increased with increasing
25(OH)D serum levels, while the fourth study reported
the opposite.18–21 None of these studies individually
showed any statistically significant associations, and the
inconclusive results may be due to difference in statistical
power, the covariate adjustments, whether CM cases had
a cancer history or not, and whether serum was sampled
before or after the CM diagnosis. Several recent studies
have reported an inverse association between Breslow
thickness and 25(OH)D serum level at diagnosis.20 22–25
As both tumour thickness and 25(OH)D level were
measured at the same time in these studies, these associations may have been affected by reverse causality.26 27
However, for prognosis after a CM diagnosis, higher diagnostic 25(OH)D levels have been shown to predict lower
risk of relapse and increased survival, independent of
Breslow thickness.22 24 A recent study ascribed the effect
on CM survival to change in 25(OH)D during follow-up
from CM diagnosis to death, and not the 25(OH)D level
at diagnosis.28
Low 25(OH)D levels are more frequent in obese
persons, suggesting that 25(OH)D deficiency is associated with obesity and vice versa.29–33 Obesity as measured
by body mass index (BMI) above 30 kg/m2 has been
positively associated with CM risk in males, but results
for women are ambiguous and possibly confounded
by personal habits as obese women may refrain from
sunseeking behaviour compared with their normal-weight
peers.11 Further, diet-induced obesity has been found to
increase CM progression in mice models.34 The biological mechanism underlying an obesity-induced increase
in CM incidence is not well understood, although
a hyperglycaemia hypothesis has been suggested.35
Another hypothesis suggests that adipocytes produce
high levels of vascular endothelial growth factor, associated with visceral fat, which contributes to angiogenesis
and tumour growth.36
The metabolic hormone leptin may be a risk factor
for both CM and CM progression. Leptin is released
by adipose tissue and plays an important role in the
regulation of insulin sensitivity and weight regulation.37 38 Increased diagnostic serum levels of leptin have
been associated with increased CM risk, possibly caused by
a leptin-induced increase in neoangiogenesis, reduction
of melanogenesis and a decreased capacity of the melanocytes’ DNA repair.39 40 Recent studies have demonstrated
that leptin receptors are present in melanoma cell lines
that proliferate in response to leptin, and that leptin
bound to its receptor stimulates melanoma growth.41–44
After a CM diagnosis, there is an increased risk of diagnosis of additional CM, as well as other cancers.45 46 For
example, the risk of lymphoma before or after CM has
2

received increased focus.47 Immune perturbation has
been suggested to contribute to the development of CM
after non-Hodgkin’s lymphoma (NHL) subtypes such
as chronic lymphocytic leukaemia/small lymphocytic
lymphoma.48 As for CM, low 25(OH)D serum levels have
also been associated with reduced survival and poor prognosis after NHL,49 50 which raises the question of whether
low 25(OH)D could alter the risk of lymphoma as a
second cancer after CM or vice versa.
Aims and hypotheses
The interplay between 25(OH)D and obesity and
their relation to CM is poorly described, and increased
knowledge of these factors is warranted to improve CM
prevention and prognosis. In the present study protocol,
we propose a set of prospective cohort and nested case–
control studies with the primary aim of examining BMI
and serum levels of 25(OH)D and leptin in relation to
CM risk, Breslow thickness and mortality, and risk of
second cancer and survival after a CM diagnosis. As a
secondary aim, we propose a nested case–control study
of lymphoma risk after CM and vice versa, in relation to
serum levels of 25(OH)D and leptin.
We hypothesise that:
1. High prediagostic BMI (≥30 kg/m2, quantiles,
continuous) is associated with
►► Increased CM risk, Breslow thickness and
mortality;
►► Reduced survival after a CM diagnosis;
►► Increased risk of contracting CM followed by a
second cancer (n=292 851);
►► Increased risk of second cancer among CM
survivors (n ≈ 3000).
2. High prediagnostic serum levels of leptin (>4 ng/mL,
highest quantile, continuous) and low prediagnostic
25(OH)D levels (<30 nmol/L, lowest quantile,
continuous) are associated with
►► Increased CM risk and Breslow thickness;
►► Reduced survival after a CM diagnosis;
►► Increased risk of contracting CM followed by a
second cancer compared with no cancer history;
►► Increased risk of second cancer among CM
survivors;
►► Increased lymphoma risk after a CM diagnosis
and vice versa compared with no cancer history.
Methods and analysis
Study population and data sources
Janus Serum Bank Cohort
This project is based on the Janus Serum Bank Cohort, a
population-based biobank for prospective cancer studies
containing serum samples and questionnaire data from
292 851 Norwegians who participated in five health
surveys 1972–2003. A detailed description of the Janus
Serum Bank Cohort (hereafter Janus Cohort), its data
and establishment, is published elsewhere.51 The Janus
Cohort includes participants from the following surveys:
Stenehjem JS, et al. BMJ Open 2017;7:e014829. doi:10.1136/bmjopen-2016-014829
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Figure 1 Overview of linkage between different data sources. BMI, body mass index; ERY, erythemally weighted UVR; PIN,
personal identification number; UVR, ultraviolet radiation.

1. The Oslo Study I (1972–1973) invited men residing in
Oslo aged 20–49 years.
2. The Norwegian Counties Study was carried out as a
three-wave survey (1974–1978, 1977–1983 and 1985–
1988), inviting men and women aged 20–49 years
residing in Finnmark, Oppland or Sogn og Fjordane.
3. Oslo Age 40 Programme invited men and women
aged 40 residing in Oslo 1981–1999.
4. The National Age 40 Programme triennially invited
all men and women aged 40–42 years in all Norwegian
counties during 1985–1999.
5. The TROFINN Health Study invited all men and
women aged 30–75 years residing in Troms and
Finnmark in 2001–2003.
Blood serum samples
The Janus Cohort has detailed sample information
including date of sample collection and county of residence at sample collection. The samples have been stored
at –25°C for up to 43 years.51 Serum samples of 25(OH)D
and leptin have been demonstrated to have high stability
after long-term storage,52 53 and previous studies have
shown that serum from the Janus Cohort is well suited
for analyses of 25(OH)D54 55 and leptin.56 57 Although
the storage condition at −25°C is not ideal, a possible
Stenehjem JS, et al. BMJ Open 2017;7:e014829. doi:10.1136/bmjopen-2016-014829

time-dependent degradation may be partly compensated
for by matching cases and controls on time of blood draw.
Height and weight measurements and questionnaire data
Together with blood sample collection, standardised
height and weight measurements were taken by trained
personnel. Participants in the surveys were also asked
to complete questionnaires on smoking habits, alcohol
consumption, diet, physical activity, use of medications
etc. Slightly different questionnaires (different wording
and number of response categories) were used in the five
health surveys, and a set of variables has been harmonised.58 For the present project, the following variables are
available: height (cm), weight (kg), BMI (kg/m2 and categorised as 12–18.49, 18.5–24.9, 25.0–29.9, ≥30),59 smoking
status (never, former, current), cigarettes per day (1–9,
10–14, ≥15), years of smoking (1–9, 10–29, ≥30), time
since smoking cessation (<3 months, 3 months–1 year,
1–5 years, >5 years), level of total physical activity (inactive, low, medium, high) and level of physical activity at
work (sedentary, walking, walking and lifting, heavy physical work).
Linking the Janus Cohort to population-based registries
Every resident in Norway is assigned a unique 11-digit
personal identification number (PIN), which ensures a
3
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correct linkage of the Janus Cohort to population-based
registries and databases as described below and in figure 1.
Population-based registries
The Cancer Registry of Norway (CRN) has registered all
new cancer diagnoses in Norway since 1953. Reporting
of incident cancers to the CRN is compulsory by law, and
information from pathologists, general practitioners, the
Norwegian Patient Registry and the Norwegian Cause
of Death Registry ensures a high degree of completeness (overall 98.8%).3 For the present project, incident
cancers from 1972 through 2014 will be linked to the Janus
Cohort. The following cancer information will be used:
date of diagnosis (month and year), tumour localisation
(International Classification of Diseases seventh revision
(ICD-7 codes) converted into ICD-10 codes), histology
(codes from ICD-Oncology second and third revisions),
clinical stage (local=no metastases, regional=metastasis in
regional lymph nodes or surrounding area, distant=distant metastasis) and Breslow thickness (mm).
Date and cause of death (death from cancer and death
from causes other than cancer) will be obtained from the
Cause of Death Registry and vital status (alive, emigrated
or dead) with corresponding dates will be obtained from
the National Population Registry.
Data on occupation at baseline (categorised as indoor/
outdoor/mixed and high risk/medium risk/low risk for
UVR exposure) and highest attained educational level at
baseline (none, compulsory, upper secondary, college/
university) will be obtained from Statistics Norway.
UVR exposure matrices
County-specific, yearly average doses of ultraviolet A
(UVA), ultraviolet B (UVB) and erythemally weighted
UVR (ERY) will be calculated and assigned to each
participant, according to place of residence, at baseline
and cumulated throughout follow-up (ie, until cancer,
emigration, death or 31 December 2014, whichever
occurs first). The UVR exposure matrices will be based
on measurement data from UV-network stations operated by the Norwegian Radiation Protection Authority
and on modelled values as described by Medhaug et al.60
Furthermore, age-specific, county-specific and time period-specific data on sunburns, sunbathing vacations and
solarium (women only) use will be linked to the Janus
Cohort on a group level as derived from questionnaire
data collected in the Norwegian Women and Cancer

Figure 2

4

study.61 62 Surveys conducted by the Norwegian Cancer
Society show small gender differences with respect to
frequency of sunburns and sunbathing vacations among
Norwegian women and men.63 This is also supported by
almost identical CM incidence rates between men and
women in Norway in the past 60 years.64
Study designs
Study I: a prospective cohort study
In a prospective cohort study among all 292 851 individuals in the Janus Cohort (study sample I in figure 2), we
will explore baseline BMI in relation to CM risk, Breslow
thickness and mortality (hypothesis 1.1), survival after a
CM diagnosis (hypothesis 1.2) and risk of second cancer
after CM (hypotheses 1.3 and 1.4). Hypotheses 1.3 and 1.4
differ by use of study sample; hypothesis 1.3 includes all
292 851 individuals in the Janus Cohort, while hypothesis
1.4 includes only the 3000 CM cases. Sex-specific analyses
exploring the potential confounding effects from age,
UVR exposure, smoking and education will be conducted
for all analyses in study I.
Studies II–IV: prospective nested case–control studies
Three prospective case–control studies will be nested
within the Janus Cohort (study samples II–IV in figure 2).
For serum analyses, the nested case–control design is
cost-efficient compared with the cohort design as only
a limited number of CM cases and cancer-free controls
are selected and matched using an incidence-density
sampling scheme.65 Also, the nested case–control design
takes advantage of the prospective nature of the cohort
study by using data and serum samples collected before
any cancer diagnosis, thereby reducing the potential for
bias. Table 1 gives a complete description of the case,
control and matching criteria.
Study II
Study II will examine CM risk and Breslow thickness
according to prediagnostic serum levels of 25(OH)
D and leptin (hypothesis 2.1). We will study CM cases
(II a; figure 2) without a history of cancer and controls
alive and without a cancer history at the time of the case
diagnosis (II b). We will include one control per case,
matched on sex, age at serum sampling and season due
to seasonal variation in 25(OH)D levels (table 1). UVR
exposure, smoking and education will be adjusted for.
Survival analysis (as in study I) will be undertaken on

Overview of study samples and overlap between cases and controls between studies.
Stenehjem JS, et al. BMJ Open 2017;7:e014829. doi:10.1136/bmjopen-2016-014829
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Table 1 Overview of case, control and matching criteria for studies II–IV
Case criteria
 Cases (n)

Study II

Study III

700

345

Study IV
60

 Verification

Histologically or
Histologically or cytologically verified second
cytologically verified
cancer after CM in the Janus Cohort (ICD-10:
CM in the Janus Cohort C43 + any type).
(ICD-10: C43).

Histologically or
cytologically verified
CM+lymphoma+CM in
the Janus Cohort
(ICD-10:
C43 + ICD-O-3* or
ICD-O-3* + C43)

 Definition

CM cases without a
cancer history (not tied
on date with another
diagnosis)

Lymphoma after first
primary CM diagnosis or
vice versa

 Selection

Sampled at random
All available cases from study II + randomly
from a pool of available sampled from CM pool
CM cases

 Age at diagnosis

<75 years

 Year of diagnosis

<2009

 Minimum time
from blood draw to
diagnosis

2 years

 Sex

Male or female

Second cancers (any type) after first primary CM
diagnosis

All available cases
from study III and IV +
randomly sampled from
pool

Control criteria
 Control group

II b

III b

III c

IV b

 Controls (n)

700

345

345

180

 Definition†

Alive, resident in
Norway and no cancer
history before case
diagnosis

Alive, resident in Norway
and no cancer history
before diagnosis of
second cancer

Alive, resident in Norway Alive, resident in Norway
and a CM diagnosis
and no cancer history
but no second cancer
before case diagnosis
before diagnosis of
second cancer

 Selection

Random sampling with replacement from a pool of available controls

Matching criteria
 Sex

Same sex as case

 Age at blood draw

±2 years from age of case at blood draw. Stepwise extension by ±3 months up to ±3 years if
necessary

 Time period of blood The following 3-month intervals: (a) December–February, (b) March–May, (c) June–August, (d)
draw
September–November
 Date of CM diagnosis Only applies to control group III c: ±6 months. Stepwise extension by ±1 months up to ±1 year if
necessary.
*9727, 9728, 9729, 9835, 9836, 9837, 9670, 9823, 9731, 9734, 9732, 9733, 9675, 9678, 9679, 9680, 9684, 9591, 9760, 9671, 9761, 9762,
9673, 9690, 9691, 9695, 9698, 9687, 9826, 9689, 9699, 9764, 9700, 9701, 9709, 9718, 9708, 9702, 9705, 9714, 9716, 9717, 9948, 9719,
9827, 9831, 9834 9833, 9940, 9820, 9832 9590, 9750.
†Allow only common cancers (colon, breast, prostate, skin and lung only) after date of diagnosis of case to conserve sera of rare cancers for
later studies.
CM, cutaneous melanoma; ICD-10, International Classification of Diseases, 10th revision.

the subsample of CM cases (II a) with measured 25(OH)
D and leptin (hypothesis 2.2). Covariates included in
study I will be taken into account.
Study III
In study III, we will examine the risk of second cancer
after a CM diagnosis according to prediagnostic
Stenehjem JS, et al. BMJ Open 2017;7:e014829. doi:10.1136/bmjopen-2016-014829

serum levels of 25(OH)D and leptin (hypotheses
2.3 and 2.4). CM cases with a second cancer (III
a; figure 2) and controls without a cancer history at
the time of the second cancer diagnosis (III b) will
be selected to address hypothesis 2.3. For hypothesis 2.4, controls with a CM diagnosis at the time of
the second cancer diagnosis will be selected (III
5
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c). We will include one control per case, matched
on sex, age at serum sampling and season of serum
sampling (table 1). In addition, control group III c
will be matched on date of the CM diagnosis (table 1).
Covariates included in studies I–II will be taken into
account.
Study IV
A group including cases (IV a; figure 2) with CM before
lymphoma or vice versa and controls (IV b) with no
cancer history at the time of the second cancer diagnosis
will be examined according to prediagnostic serum levels
of 25(OH)D and leptin (hypothesis 2.5). All case–control
pairs will be matched on sex, age at serum sampling and
season of serum sampling (table 1). Covariates included
in studies I–III will be taken into account.
Power and sample size calculations
Study I
With the large study sample (n=292 851), including more
than 3000 CM cases by 31 December 2014, we have sufficient statistical power to reveal minor risk differences
between the BMI categories, normal weight (18.5–24.9 kg/
m2), overweight (25–29.9 kg/m2) and obese (≥30 kg/m2).
Thus, further power calculation is not conducted.
Studies II–IV
Study II will include 700 CM cases of the approximately
3000 available. Study III will include 345 cases with a
second primary cancer after CM and study IV will include
60 cases of lymphoma after CM or vice versa, which
were the total number of cases in the Janus Cohort by
31 December 2014. Table 2 shows the smallest detectable
OR according to assumed proportion of controls exposed
to low serum levels of 25(OH)D and high leptin levels
when using a power of 0.80 and a significance level of
0.05. The assumed proportions of exposed controls were
based on previous studies conducted on serum samples
from the Janus Cohort. For 25(OH)D, a study on prostate
cancer reported that 4.4% and 30.6% of the controls had
25(OH)D levels below 30 nmol/L and 50 nmol/L, respectively.54 For leptin, a study on colon cancer reported that

Table 2 Smallest detectable OR (above the null) according
to proportion of controls exposed to low vitamin D (25(OH)
D) and high leptin levels, using a power of 0.80 and a
significance level of 0.05
Proportion
of exposed
controls

Study II
Cases=700,
ratio=1:1

Study III
Cases=345,
ratio=1:1

Study IV
Cases=60,
ratio=1:3

5%*
30%†
20%‡

1.82
1.37
1.43

2.26
1.57
1.65

3.81
2.34
–

*Exposure = 25(OH)D <30 nmol /L.
†Exposure = 25(OH)D <50 nmol /L.
‡Exposure = high serum leptin levels ≥4.1 ng/mL).
25(OH)D, 25-hydroxyvitamin D.

6

20% of the controls had a leptin level of 4.1 ng/mL or
higher.56
Data management
Case–control selection
As indicated in figure 2, there will be some overlap
between cases and controls between the studies. CM cases
(II a) will be sampled at random from all available CM
cases in the Janus Cohort, independent of second cancer
status. However, some of the CM cases (II a) may have
developed a new cancer and then be eligible for use in
study III as CMs with a second cancer (III a). Controls
(II b) will be sampled at random with replacement (incidence-density sampling) from the Janus Cohort and
matched to CM cases (II a). Also, controls (II b) matched
to the CM cases (II a) who developed a second cancer (III
a) will be eligible for use in study III (group III b) if they
are alive, resident and cancer-free at the time of the CM
cases’ second cancer (III a). Cases from study II (II a) may
be reused as controls in study III (III c) if they fulfil the
matching criteria (table 1). The remaining case–control
pairs for study III will be sampled from the Janus Cohort.
Study IV will follow the same approach as studies II and
III with respect to reuse. A picking list of unique serum
samples for all studies will be prepared by a data manager
for the Janus Serum Bank Cohort laboratory team.
Laboratory analyses
The Janus Serum Bank laboratory team will send 220 µL
aliquots of serum to the Hormone Laboratory at Oslo
University Hospital for analyses of 25(OH)D and leptin.
The laboratory participated in the Vitamin D External
Quality Assessment Scheme for total 25(OH)D. The
Hormone Laboratory is accredited by the Norwegian
Accreditation as a testing laboratory and complies with
the requirements of the NS-EN ISO/IEC 17025 standards.
Serum concentrations of 25(OH)D will be determined
by an in-house developed liquid chromatography/tandem
mass spectrometry method. In brief, after protein precipitation, 25(OH)D will be extracted from samples using
phospholipid depletion plates. Separation is achieved
by reversed-phase chromatography and the isobaric C3
epimer 3-epi-25(OH)D3 will be separated from 25(OH)
D3. Mass spectrometric detection will be performed
by electrospray ionisation and triple quadruple ion
separation (multiple reaction monitoring).66 Serum
concentrations of leptin will be determined by using EMD
Millipore Human Leptin Radioimmunoassay as described
in Lee et al.67
Hormone Laboratory staff will be blinded to case–
control status. Two identical quality control (QC) samples
with serum from a pool of several persons will be placed
on each batch. These two QC samples will change position for each new batch to avoid bias from weak spots
in the machine/kit and will thus take into account both
inter-batch variability and intra-batch variability. Each
case–control pair will be placed and analysed on the same
batch.
Stenehjem JS, et al. BMJ Open 2017;7:e014829. doi:10.1136/bmjopen-2016-014829
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Statistical methods
In the cohort studies, we will use Poisson and Cox
regression and estimate relative risks with 95% CIs.
Spline models will also be explored if a non-linear relationship between exposure and outcome is assumed.
In the nested case–control studies, conditional logistic
regression will be applied to estimate ORs with 95%
CIs. A multilevel approach will be applied for analyses
containing group-level data. Directed acyclic graphs
will be used in the process to select variables to include
in the statistical models. Confounding variables will be
included in the models and tests of interaction effects
will be performed when relevant. In the case of interaction effects, stratified results will be presented. All tests
will be two-sided and p<0.05 will be considered statistically significant. All statistical analyses will be performed
using Stata.
Analysis plan
We plan to conduct the following analyses to test our
hypotheses:
►► Hypothesis 1.1: A prospective cohort analysis of
prediagnostic BMI and other anthropometric
measures in relation to CM risk, Breslow thickness
and mortality using the complete Janus Cohort
(n=292 851).
►► Hypothesis 1.2: A prospective analysis of survival
after a CM diagnosis, according to prediagnostic
BMI (n ≈ 3000).
►► Hypothesis 1.3: A prospective cohort analysis of
prediagnostic BMI and the risk of second cancer
after a CM diagnosis using the complete Janus
Cohort (n=292 851).
►► Hypothesis 1.4: A prospective cohort analysis of
prediagnostic BMI and the risk of second cancer
among CM survivors (n ≈ 3000).
►► Hypothesis 2.1: A nested case–control analysis of CM
risk and Breslow thickness according to prediagnostic
serum levels of 25(OH)D and leptin in 700 pairs.
►► Hypothesis 2.2: A prospective analysis of survival after
a CM diagnosis (n=700) according to prediagnostic
serum levels of 25(OH)D and leptin.
►► Hypothesis 2.3: A nested case–control analysis of risk
of second cancer after a CM diagnosis according to
prediagnostic serum levels of 25(OH)D and leptin.
Using 345 pairs of cases with CM + a second cancer
and controls without a cancer history.
►► Hypothesis 2.4: A nested case–control analysis of risk
of second cancer among CM survivors according to
prediagnostic serum levels of 25(OH)D and leptin.
Using 345 pairs of cases with CM + a second cancer
and controls with a CM diagnosis.
►► Hypothesis 2.5: A nested case–control analysis
investigating risk of lymphoma after CM or vice versa
according to prediagnostic serum levels of 25(OH)
D (n=60 cases) compared with controls without a
cancer history.
Stenehjem JS, et al. BMJ Open 2017;7:e014829. doi:10.1136/bmjopen-2016-014829

Project strengths and limitations
A major strength of the project is the linkage of multiple
data sources by use of the PIN, thereby establishing a
comprehensive research file with independently and
prospectively collected data, and a complete control of
loss to follow-up. An important strength is also the use
of high-quality cancer data with over 3000 CM cases
from a population-based registry relying on compulsory
reporting of incident cancers. Further, the prediagnostic
serum samples assure a clear prospective temporal relationship between exposure and cancer, which limits the
possibility of reverse causality, that is, that the cancer or
its precursor affects the 25(OH)D or leptin serum levels.
An important limitation of the project is that we will
only be able to obtain group-level data on UVR exposure
(ambient UVA, UVB and ERY; sunburns, sunbathing vacations and solarium use), but our data will capture variation
in these variables by age, time period and between counties. However, the long and complete time series, covering
the whole observation period and early childhood for
many of the participants, enables analysis with time-varying
UVR exposure. Another limitation is the lack of data on
pigmentary characteristics and number of naevi. Also,
differences in skin colour between cases and controls could
potentially bias our estimates. However, the average fraction of non-whites during 1970–1991 (when 97% of the
Janus Cohort was established) was less than 1% of the total
Norwegian population,68 and hence we consider the risk of
introducing bias by not taking individual information on
skin colour into account as negligible.
Ethics and dissemination
The project has a running approval from the Regional
Committee for Medical and Health Research Ethics to
link the different population-based registries to establish
a deidentified research file. In addition, each registry
and data source has approved that its data will be linked
and used in a deidentified research file. A linkage key
consisting of the 11-digit PIN and a project-specific ID
number will be stored and governed by a third party
unavailable to the research team. Moreover, participation in each of the health surveys constituting the Janus
Cohort was voluntary and based on informed consent.
All results will be published in relevant peer-reviewed
international scientific journals and presented at conferences, nationally and internationally. Results will also
be directly communicated to user groups such as the
Norwegian Cancer Society, The Norwegian Melanoma
Association, and to health authorities and clinicians. Both
the annual Norwegian conferences (‘Oncologic Forum’,
the Norwegian Melanoma Group Meeting) and international conferences will serve as platforms for knowledge
distribution to clinicians and researchers. Important
results will also be disseminated through press releases.
Further, lectures, the CRN website, social media and
other potential channels will also be used to reach patient
organisations, patients and the general public.
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